Immune checkpoint inhibitors (ICIs), such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed death-1 (PD-1), and its ligand (PD-L1), represent a breakthrough in cancer treatment that successfully increases the survival rate of the patients [1, 2]. Here, CTLA4 is linked to cancer.